Data as of Oct 17
| +0.59 / +2.66%|
The 6 analysts offering 12-month price forecasts for Hyperion Therapeutics Inc have a median target of 37.50, with a high estimate of 42.00 and a low estimate of 35.00. The median estimate represents a +64.76% increase from the last price of 22.76.
The current consensus among 6 polled investment analysts is to Buy stock in Hyperion Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.